SMERUD MEDICAL RESEARCH UK LIMITED

Their core work

Smerud Medical Research is a contract research organization (CRO) with deep expertise in rare and orphan disease clinical development. They design, manage, and deliver clinical trials — from regulatory strategy through pivotal Phase IIb studies — for small biotech companies and academic consortia that lack in-house clinical operations. Their H2020 involvement as a third-party service provider reflects their typical commercial model: they are not grant recipients but paid experts embedded into research consortia to handle the clinical and regulatory workload. Their portfolio spans ophthalmic regenerative therapies and inhaled respiratory treatments, indicating broad rare-disease CRO capability rather than single-indication focus.

What they specialise in

How they've shifted over time

In their earliest H2020 engagement (2017), Smerud was involved in regenerative medicine for retinal disease — working with RPE cell biology, lipofuscin clearance, and depigmentation, all characteristic of earlier-stage mechanistic research in a highly specialized ophthalmology niche. By 2018, their focus had shifted decisively toward late-stage clinical execution: a pivotal Phase IIb trial for cystic fibrosis, with keywords emphasizing clinical development infrastructure and mutation-independent delivery. This trajectory suggests a CRO maturing from supporting exploratory therapeutic research toward anchoring fully regulatory-grade pivotal programs.

Smerud is moving toward higher-stakes, later-stage clinical development roles — a partner to bring in when a rare-disease program is ready to generate pivotal evidence for regulatory submission, not when it is still in the lab.

How they like to work

Smerud participates exclusively as a third party, meaning they are contracted service providers rather than co-applicants — they bring specialized CRO execution capacity without seeking grant funding themselves. This model suits consortia led by academic or biotech principals who need clinical trial operations expertise without building it internally. With 15 distinct partners across 6 countries from just 2 projects, they operate inside moderately large, international consortia, suggesting comfort navigating multi-stakeholder clinical programs.

Smerud has connected with 15 unique consortium partners across 6 countries despite only two H2020 projects, indicating dense, multi-partner consortia rather than bilateral arrangements. Their geographic reach is European, consistent with a UK-based CRO serving the EU rare-disease biotech ecosystem.

What sets them apart

As an SME CRO focused specifically on rare and orphan diseases, Smerud fills a gap between large generalist CROs (too expensive, too process-heavy) and purely academic clinical units (lacking regulatory execution capacity). Their willingness to operate as a third party makes them attractive to H2020 consortia that need professional clinical management without adding a funding competitor. For a biotech company or research team with a promising rare-disease asset and no clinical operations team, Smerud is the type of partner that turns a research hypothesis into a pivotal trial dossier.

Highlights from their portfolio

• OligoGpivotalCF
  A pivotal Phase IIb trial — the highest-stakes clinical evidence generation stage before regulatory submission — for an inhaled mutation-independent cystic fibrosis therapy, representing Smerud's most operationally demanding and clinically significant H2020 contribution.
• Soraprazan
  An early regenerative therapy program targeting lipofuscin-driven RPE degeneration in Stargardt's disease, a rare inherited retinal dystrophy with very few treatment options, illustrating Smerud's ability to operate in ultra-niche ophthalmic indications.